Toggle navigation
Home
Feed
Channels
Profile
Home
Feed
Channels
Profile
Shambavi Richard's Talks
Shambavi Richard
Mount Sinai
HDP-101: Phase I/IIa Trial Design in Relapsed/Refractory Myeloma
July 31, 2026
Shambavi Richard
Mount Sinai
00:00
--:--
HDP-101: An Amanitin-Based BCMA-Targeted Antibody-Drug Conjugate
July 31, 2026
Share
HDP-101: An Amanitin-Based BCMA-Targeted Antibody-Drug Conjugate
https://www.medspoke.co/channel_playlist?object_id=874&tap_id=13231
Copy Link
Email
X
Bluesky
WhatsApp
LinkedIn
Facebook
Reddit
Shambavi Richard
Mount Sinai
DURGA-1 Trial: Conclusion & Key Takeaway
July 31, 2026
Why are you reporting this TALK?
